Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer.

Nature communications·2026

Same author

Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials.

European urology·2026

Same author

[<sup>177</sup>Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study.

The Lancet. Oncology·2026

Same author

Personalized Immunotherapy for T Cell Lymphomas: From Immune Escape to Precision Therapeutics.

Journal of personalized medicine·2025

Same author

Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Same author

Immunological responses to brain metastasis stereotactic radiosurgery in patient-matched longitudinal blood and tumour samples.

Clinical and translational radiation oncology·2024

Search research articles

Related Experiment Video

Updated: Mar 24, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Allogeneic CAR19 cells clear ALL.

¹PETER MACCALLUM CANCER CENTER.

|March 12, 2016

Summary

This summary is machine-generated.

Allogeneic donor chimeric antigen receptor T cells (CAR19) offer a promising alternative for treating acute lymphoblastic leukemia (ALL) when autologous CAR19 cell production is challenging due to patient T-cell dysfunction.

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

Related Experiment Videos

Last Updated: Mar 24, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

Area of Science:

Immunotherapy
Hematologic Malignancies
Cellular Therapy

Background:

Chimeric antigen receptor T cells targeting CD19 (CAR19) are effective for CD19+ acute lymphoblastic leukemia (ALL).
Autologous CAR19 cell production is often hindered by patient T-cell dysfunction from disease or treatment.
Alternative CAR19 cell sources are needed for ALL treatment.

Purpose of the Study:

To investigate the efficacy of allogeneic donor CAR19 cells in treating ALL.
To evaluate the feasibility of using donor-derived CAR19 cells in a preclinical model.

Main Methods:

Utilized a minor mismatch bone marrow transplant mouse model.
Administered allogeneic donor CAR19 cells to ALL-bearing mice.

Main Results:

Allogeneic donor CAR19 cells demonstrated therapeutic potential in the ALL mouse model.
This approach circumvents issues associated with autologous CAR19 cell generation.

Conclusions:

Allogeneic donor CAR19 cells represent a viable strategy for ALL treatment.
This method addresses limitations in autologous cell therapy for leukemia patients.